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Summary
Methionine adenosyltransferase (MAT) I/III deficiency,
caused by mutations in the MAT1A gene, is character-
ized by persistent hypermethioninemia without elevated
homocysteine or tyrosine. Clinical manifestations are
variable and poorly understood, although a number of
individuals with homozygous null mutations inMAT1A
have neurological problems, including brain demyelin-
ation. We analyzed MAT1A in seven hypermethioni-
nemic individuals, to provide insight into the relation-
ship between genotype and phenotype. We identified six
novel mutations and demonstrated that mutations re-
sulting in high plasma methionines may signal clinical
difficulties. Two patients—a compound heterozygote for
truncating and severely inactivating missense mutations
and a homozygote for an aberrant splicingMAT1Amu-
tation—have plasma methionine in the 1,226–1,870 mM
range (normal 5–35 mM) and manifest abnormalities of
the brain gray matter or signs of brain demyelination.
Another compound heterozygote for truncating and
inactivating missense mutations has 770–1,240 mM
plasma methionine and mild cognitive impairment. Four
individuals carrying either two inactivating missense
mutations or the single-allelic R264H mutation have
105–467 mM plasma methionine and are clinically un-
affected. Our data underscore the necessity of further
studies to firmly establish the relationship between gen-
otypes in MAT I/III deficiency and clinical phenotypes,
to elucidate the molecular bases of variability in mani-
festations of MAT1A mutations.
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Introduction
Methionine adenosyltransferase (MAT) (E.C.2.5.1.6)
catalyzes an unusual two-step reaction that involves the
transfer of the adenosyl moiety of ATP to methionine
to form S-adenosylmethionine (AdoMet), with the con-
comitant formation of a tripolyphosphate that is then
cleaved to PPi and Pi (Cantoni 1953; Mudd 1962). The
importance of the product AdoMet cannot be overem-
phasized: it is the source of methyl groups for most bi-
ological methylations (Mudd et al. 1995a). All organ-
isms have one or two genes that encode MAT isozymes
(Kotb and Geller 1993; Mato et al. 1997). The two
human genes,MAT1A andMAT2A, are located on chro-
mosomes 10 and 2, respectively (De La Rosa et al. 1995;
Chamberlin et al. 1996). The gene products have similar
catalytic activities but vary in pattern of expression and
kinetic parameters (Kotb and Geller 1993; Kotb et al.
1997; Mato et al. 1997). MAT isozymes can be sepa-
rated by gel chromatography into three species—MAT
I, MAT II, and MAT III (Kotb and Geller 1993). MAT
I and MAT III are homotetramers and homodimers of
the a1 subunit, encoded by the MAT1A gene (Ubagai
et al. 1995; Kotb et al. 1997; Mato et al. 1997). MAT
II is an oligomer containing two moieties of the high-
ly homologous a2 catalytic subunit, encoded by the
MAT2A gene and separately encoded regulatory sub-
unit(s).MAT1A is expressed solely in adult liver (Alvarez
et al. 1993), whereas MAT2A is expressed in virtually
all tissues, including (at a low concentration) adult liver
(Kotb and Kredich 1985; Mitsui et al. 1988; Horikawa
and Tsukada 1992; De La Rosa et al. 1995). All three
MAT isozymes therefore contribute to MAT activity in
adult liver. For clarity, we refer to the gene products of
MAT1A as “MAT I/III” (Kotb et al. 1997) rather than
“hepatic MAT,” a term used formerly (Mudd et al.
1995a).
Our laboratory has demonstrated that mutations in
MAT1A that abolish or greatly reduce MAT I/III activity
cause a persistent form of hypermethioninemia (Ubagai
et al. 1995). In MAT I/III deficiency, the hypermethion-
inemia is not accompanied by elevated plasma-free ho-
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mocystine, as it is in cystathionine b-synthase deficiency;
elevated tyrosine, as in tyrosinemia type I; or severe he-
patocellular disease (Mudd et al. 1995b). MostMAT1A
mutations are transmitted in an autosomal recessive
manner, but autosomal dominant inheritance has also
been observed (Blom et al. 1992; Mudd et al. 1995b;
Chamberlin et al. 1997; Nagao and Oyanagi 1997). The
dominant trait, in all cases described thus far, is due to
heterozygosity for an R264H mutation (Chamberlin et
al. 1997; Nagao and Oyanagi 1997), which seems to
render dimers formed between mutant and wild-type
subunits inactive (Chamberlin et al. 1997).
The clinical consequences of MAT I/III deficiency are
poorly understood. In some individuals, this deficiency
is apparently benign; in others, association of neurolog-
ical problems with null mutations in the MAT1A gene
has been observed (Surtees et al. 1991; Chamberlin et
al. 1996). Thus, it is of interest to continue to define the
molecular nature of MAT1A mutations in hypermeth-
ioninemic individuals and to investigate possible corre-
lations between genotype and clinical severity. In the
present study, we report molecular analyses of the
MAT1A gene of seven previously uncharacterized hy-
permethioninemic individuals with neurodevelopmental
status and neuroimaging ranging from normal to mark-
edly abnormal.
Subjects and Methods
Subjects
We have analyzed the MAT1A genes of seven indi-
viduals with isolated persistent hypermethioninemia.
Clinical and metabolic aspects of patients 1, 5, 7, and
14 have been reported elsewhere (Mudd et al. 1995b).
The three individuals new to the study are patient 31,
patient BII-1, and patient BI-1 (father of patient BII-1).
Analysis of the MAT1A Gene by SSCP and DNA
Sequencing
Genomic DNA was extracted from blood samples. All
peripheral blood samples were obtained with the in-
formed consent of the donors or their parents. Each exon
of the MAT1A gene coding region was amplified
as described elsewhere (Chamberlin et al. 1996), and
the products were analyzed on mutation-detection–
enhancement nondenaturing gels (AT Biochem) with or
without 5% glycerol. Mutations were identified by se-
quencing at least five subclones of each. Direct sequenc-
ing was performed on MAT1A exon VIII of patient 14
and of her parents, by means of a Cyclist Exo-Pfu DNA
sequencing kit (Stratagene).
Construction, Expression, and Enzymatic Activity of
MAT1A Mutants
Mutant cDNAs were constructed as described else-
where (Ubagai et al. 1995) and were subcloned into
either pQE30 (QIAexpress system; QIAGEN), for ex-
pression in bacteria, or pSVL, for expression in COS-1
cells. Expression of wild-type or mutantMAT1A cDNAs
in bacteria or COS-1 cells was achieved as described
elsewhere (Chamberlin et al. 1996). MAT activity was
determined from bacterial or COS-1 extracts containing
approximately equal amounts of expressedMAT protein
(as estimated by western-blot analysis), as described else-
where (Chamberlin et al. 1996).
Minigene Construction
To examine a possible splice-donor mutation in exon
III of patient 7, four MAT1A minigenes—containing 46
bp of exon III 3′-region, part of intron III, and 88 bp of
exon IV 5′-region—were constructed as templates, by
means of genomic DNAs from patient 7 and a normal
subject. MAT1A intron III is 3,120 bp in length, con-
taining MscI sites at nucleotides 171 and 2913 as well
as PstI sites at nucleotides 728 and 2831. Minigene set
I contained 378 bp of intron III (deletion of nucleotides
174–2915 of intron III), and minigene set II contained
1,017 bp of intron III (deletion of nucleotides 733–2835
of intron III) (see fig. 1A). Primers used to construct
minigene set I are XhE3S (5′-GTGAGGGACACCAT-
CAA-3′, nucleotides 247–263 of MAT1A cDNA) and
XbE4AS (5′-TCATTTCTGTCCAGATG-3′, nucleotides
364–380 of MAT1A cDNA), containing either an XhoI
or an XbaI site at the 5′ end, MscIAS (5′-TGGCC-
ATCCTTATGCCAGAGT-3′, nucleotides 156–176 of
MAT1A intron III), and MscIS (5′-TGGCCAAAGAG-
TTCTACATGA-3′, nucleotides 2913–2933 of MAT1A
intron III), containing anMscI site at the 5′ end. Primers
used to construct minigene set II are E3S, E4AS, PstIAS
(5′-CTGCAGAATGTGATCGCATAC-3′, nucleotides
713–733 of MAT1A intron III), and PstIS (5′-CTGCA-
GGTCTCTGTAGGATGT-3′, nucleotides 2831–2851 of
MAT1A intron III), containing a PstI site at the 5′ end.
Each minigene was constructed by amplifying the exon
III/intron III junction region and the intron III/exon IV
region separately, by means of an Expand Hi Fidelity
PCR system (Boehringer-Mannheim). The exon III/in-
tron III fragments were digested with XhoI and MscI
(set I) or XhoI and PstI (set II), and the intron III/exon
IV fragments were digested with XbaI and MscI (set I)
or XbaI and PstI (set II). The digested fragments were
purified and used for three-way ligations in the presence
of a pSVL vector digested with XhoI and XbaI. Clones
with the correct inserts (512 and 1,151 bp for minigene
set I and II, respectively) were sequenced at the exon/
intron borders, to confirm their identity.
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Assay for Correct Splicing of Minigenes
A minigene or a vector control was transfected into
COS-1 cells, as described by Chamberlin et al. (1996),
and total RNA was isolated by use of an RNEasy RNA
isolation kit (QIAGEN), followed by DNase I digestion.
First-strand synthesis was performed on ∼16 ng total
RNA from each sample by means of a cDNA synthesis
kit (Pharmacia) and 100 pmol of a primer derived from
the pSVL sequence that includes the polyadenylation sig-
nal (5′-TTTATTGCAGCTTATAATGG-3′, nucleotides
1639–1659; see schematic, fig. 1A). PCR reactions were
performed on the entire first-strand synthesis mix by
addition of 40 pmol XhE3S, 33 ml H2O, and 1 ml Taq
polymerase (Life Technologies) to each reaction. Samples
were amplified for 30 cycles of 95C for 1 min, 55C
for 30 s, and 72C for 30 s, and products were analyzed
by electrophoresis through a 2% agarose gel. Correctly
spliced products should include 148 bp of vector se-
quence, 134 bp of MAT1A cDNA sequence, and 9 bp
of linker sequence and should be 291 bp in length.
Results
Hypermethioninemic Individuals Carrying Autosomal
Recessive MAT1A Mutations
Six of the seven individuals reported in this study were
initially identified by routine newborn screening for
hypermethioninemia, designed to detect homocystinuria
due to cystathionine b-synthase deficiency. BI-1 was dis-
covered during screening of the family of proband BII-
1. All seven individuals were shown to have persistent
isolated hypermethioninemia without evidence of sec-
ondary hypermethioninemia due to tyrosinemia type I,
cystathionine b-synthase deficiency, or severe hepato-
cellular disease.
Patient 1 is one of the first infants described with
confirmed deficiency of MAT activity in the liver. MAT
activity in a crude liver extract, measured in the presence
of 1 mM or 6 mM methionine, was 8%–39% of control
values, respectively (Finkelstein et al. 1975; Gout et al.
1977). Magnetic resonance imaging (MRI) performed at
age 20 years revealed anomalous signals in the gray mat-
ter and a heterogeneous hyposignal from the posterior
part of the basal ganglia (A. Joannard, personal com-
munication). At age 24 years, the patient continued to
have an elevated methionine concentration of 1,030 mM
(reference range 5–35 mM), as well as elevated methi-
onine transamination metabolites (15 mM; reference
range 0.20–0.54 mM) in plasma (Mudd et al. 1995b).
Physical examination revealed that cognitive and neu-
rological functions were normal, and the subject’s over-
all health was good.
SSCP and sequence analyses showed that patient 1 is
a compound heterozygote for two MAT1A mutations:
113GrA (fig. 2A), which converts a Ser at position 38
to an Asn (S38N; table 1), and 255delCA (fig. 2A),
which introduces a premature termination codon at po-
sition 92 (92X; table 1). Both mutations completely
abolished MAT activity (table 2). It has been reported
that rat MAT2A cDNA contains an Asn at position 38
(Horikawa et al. 1990). However, sequencing of six in-
dependent exon II isolates of the rat MAT2A gene
showed only a Ser at position 38 (data not shown),
which suggests that the original sequence was either in
error or derived from a rat strain that carries an S38N
mutation. Our data explain the already documented def-
icit in MAT activity in the liver of patient 1, a deficit
that was more severe when the assay was done at a
higher methionine concentration, as would be expected
when the relatively high Michaelis constant (Km), high
maximal velocity (Vmax) MAT I/III activity is abnormally
low, but the lower Km), lower Vmax MAT II activity is
unaffected.
Patient 5, a female born in 1984, had plasma methi-
onine concentrations in the range of 1,721–1,870 mM.
Transient hypotonia has been observed in this patient
(Mudd et al. 1995b), and she is considered to be men-
tally slow in comparison with other members of her
family. At age 7.5 years she had, on the Wechsler In-
telligence Scale for Children-Revised, a verbal score of
88 and a performance score of 84. At age 13 years, an
MRI of the brain revealed a normal result, including
normal myelination. Patient 5 was shown to be a com-
pound heterozygote for two MAT1A mutations:
791CrT (fig. 2B), which converts an Arg at position
264 to a Cys (R264C; table 1), and 1006GrA (fig. 2B),
which converts a Gly at position 336 to an Arg (G336R;
table 1). Whereas the R264C mutation virtually abol-
ished enzymatic activity, the G336R mutant retained
23% of wild-type activity (table 2).
Patient 14, a 6-year-old girl with moderately elevated
plasma methionine concentrations of 185–467 mM, has
no reported neurological problems (Mudd et al. 1995b).
Molecular analysis of herMAT1A gene revealed that she
is a compound heterozygote for two MAT1A mutations
in exon VIII (fig. 2D). The 966TrG mutation, inherited
from her father, converts an Ile at position 322 to a Met
(I322M), and the 1031ArC mutation, inherited from
her mother, converts a Glu at position 344 to an Ala
(E344A) (table 1). Both mutations diminish, but do not
completely abolish, MAT activity (table 2).
Patient 7 is a 7-year-old boy of Hispanic and black
origin. At the age of 2 wk his plasma methionine level
was 1,664 mM. During the 1st mo of life his plasma total
homocysteine levels ranged from 5 mM to a value as
high as 47.2 mM (reference range 5.4–16.2 mM). Plasma
B12 levels were not abnormally low, and several assays
of plasma folate and methylmalonate had normal find-
ings. At the age of 2 wk, pyridoxine treatment (500 mg/
350 Am. J. Hum. Genet. 66:347–355, 2000
Figure 1 RT-PCR analysis of transcripts encoded by minigenes containing wild-type or mutant splice-donor site at exon III. A, Schematic
showing four minigene constructs in pSVL. MAT1A sequence is represented by boxes (exons) and solid lines (introns). Oligonucleotide primer
is represented by arrows; vector sequence is represented by dashes. The constructs contained 46 bp of exon III 3′-region with either a G (wild
type [WT]) or an A (mutant [M]) as the last base of this exon, either 378 bp (set I) or 1,017 bp (set II) of intron III, and 88 bp of exon IV 5′-
region, as described in the Methods section. The deleted intron III regions are denoted by forked lines. B, Agarose-gel electrophoretic analysis
of RT-PCR products of transcripts expressed by minigene constructs. Lane 1, Products of minigene I-M. Lane 2, Products of minigene II-M.
Lane 3, Products of minigene I-WT. Lane 4, Products of minigene II-WT. Lane 5, Products from COS-1 cells transfected with the vector alone.
Correctly spliced products (291 bp) will include 46 bp of exon III, 88 bp of exon IV, 148 bp of vector sequence, and a 9-bp linker sequence
at the 5′ end. Lane M, HaeIII digest of FX174 DNA. Sizes are listed to the left.
d) was begun for suspected cystathionine b-synthase de-
ficiency. Two weeks later, the patient was hospitalized
for apnea, and he required intubation and ventilator
support for respiratory failure. Computed tomography
and MRI studies of the brain had normal findings. On
hospital day 19, B6 was discontinued, and respiratory
function returned in 4 d. After discharge from the hos-
pital, the patient was maintained on a methionine-re-
stricted diet, with reduction of the plasma methionine
concentration to ∼400 mM.Cystathionine b-synthase de-
ficiency was ruled out by enzyme assays of cultured skin
fibroblasts (J. Kraus, personal communication). Enzy-
matic activities assayed in the absence or presence of
pyridoxal phosphate were 19.4 and 21.1 U/mg protein,
respectively, in fibroblasts from patient 7 and were 8.5
and 10.4 U/mg protein, respectively, in fibroblasts from
a normal individual. Assays of plasma-free homocysteine
during the 1st year and at age 3.6 years revealed no
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Figure 2 SSCP analyses of PCR-amplifiedMAT1A exons on MDE gels. Exons containing mutations, as confirmed by sequencing analyses,
are shown here. A, Patient 1. B, Patient 5. C, Patient 7. D, Patient 14. E, Patients 31 and family B. F = father; M = mother.
abnormal elevation. Concern about growth retardation
and dietary compliance led to discontinuance of methi-
onine restriction at age 10 mo. Early gross motor mile-
stones were delayed, but at age 4 years 2 mo the in
dividual was developmentally appropriate. Although re-
sults of the neurological examination were normal, an
MRI of the brain revealed diffusely abnormal whitemat-
ter and patchy basal ganglia bilaterally, with an abnor-
mally high signal in the inferior aspect and an abnor-
mally high signal in the inferior midbrain. A repeat brain
MRI 14 mo later revealed no change. At age 7 years,
growth parameters were similar to those observed at age
4 years. Findings from the neurological examination
were normal, but the patient is having learning diffi-
culties. Results of a third brain MRI were no different
from those of the prior examination.
Patient 7 was shown to be homozygous for a mutation
at nucleotide 292, the last nucleotide in exon III of the
MAT1A gene (fig. 2C): 292GfgtrAfgt (table 1). If nor-
mal splicing occurs, this mutation would result in a
GlyrSer conversion at position 98 (G98S). However,
transient-expression assays showed that the G98S mu-
tant retained nearly wild-type MAT activity (data not
shown).
The 292GfgtrAfgt Mutation Causes Aberrant Splicing
of the MAT1A Transcript
Because nucleotide 292 is the last base in exon III, a
GrA change would alter the splice-donor site from
GGfgtrGAfgt, which would lead to an inappropriately
spliced MAT1A transcript. Because a liver sample from
patient 7 was not available, we investigated the aberrant-
splice hypothesis by constructing MAT1A minigenes
containing the 3′ region of exon III, part of intron III,
and the 5′ region of exon IV, cloned into the pSVL vector
(fig. 1A). The exon III/intron III junction sequence in the
minigenes contained either the normal splice-donor site
(GGfgt) or the mutated splice-donor site (GAfgt) found
in patient 7. Reverse transcription (RT)-PCR analysis of
RNA from COS-1 cells transfected with minigenes con-
taining normal splice-donor sequences gave the pre-
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Table 1
MAT1A Mutations in Isolated Persistent Hypermethioninemic Patients
Patient and Allele Mutation Location
Effect on
Coding Sequence
Plasma
Methioninea
(mM)
1:
Allele 1 113GrA Exon II S38N 770–1240
Allele 2 255delCA Exon III 92X
5:
Allele 1 791CrT Exon VII R264C 1721–1870
Allele 2 1006GrA Exon VIII G336R
14:
Allele 1 966TrG Exon VIII I322M 185–467
Allele 2 1031ArC Exon VIII E344A
7:
Allele 1 292GfgtrAfgt Exon III/intron III Splice donor 1226–1664
Allele 2 292GfgtrAfgt Exon III/intron III Splice donor
31:
Allele 1 791GrA Exon VII R264Hb 235–545
Allele 2 Normal
BII-1:
Allele 1 791GrA Exon VII R264H 233
Allele 2 Normal
BI-1:
Allele 1 791GrA Exon VII R264H 105
Allele 2 Normal
a Published in the study by Mudd et al. (1995b). Reference range for plasma methionine is 5–35 mM.
b Mutation associated with dominantly inherited hypermethioninemia.
Table 2
MAT Activity of Bacterial Extracts
Transformed with Wild-Type or Mutant
MAT1A cDNAs
Construct
MAT Activitya
(nmol/min/mg protein)
Mock .38.09
Wild type 37.522.77
S38N .00
92X .00
R264C .50.01 (.3%)
R264H .43.07 (.1%)
I322M 17.391.25 (45.8%b)
G336R 8.88.94 (22.9%)
E344A 4.87.25 (12.1%)
a Data in parentheses are percent of wild-
type activity.
b As expressed in a bacterial system. In
COS-1 cells, however, expression was 11%
of wild-type activity (Ubagai et al. 1995). (We
regard the result obtained with the bacterial
system as more accurate, because of the
markedly increased expression efficiency in
bacteria; however, the differential activity
may also be due to the inherent differences
between the two expression systems.)
dicted splice product of 291 bp (fig. 1B, lanes 3 and 4),
whereas minigenes containing the mutant splice site con-
sistently yielded abnormally larger products (fig. 1B,
lanes 1 and 2). COS-1 cells transfected with vector alone
gave no discernible products (fig. 1B, lane 5). We con-
clude that the severe hypermethioninemia in patient 7
results from a MAT1A mutation that causes incorrect
splicing of the MAT1A transcript.
R264C Behaves as an Autosomal Recessive Trait
In contrast with the autosomal dominant transmission
of the hypermethioninemia associated with the R264H
mutation (Chamberlin et al. 1997; Mudd et al. 1998),
we found that the father of patient 5, a carrier of an
R264C allele, had a normal plasma methionine level, 30
mM. Patient 5 is a compound heterozygote for two
MAT1A mutations, R264C and G336R (table 1). Our
data indicate that the R264C mutation is transmitted in
an autosomal recessive mode. Further evidence sup-
porting the autosomal recessive behavior of the R264C
allele was obtained by examination ofMAT activity after
cotransfection of wild-type (R264) and mutant (R264C)
MAT1A cDNAs into COS-1 cells. When R264 and
R264C cDNAs were cotransfected at a ratio of 1:1, an
MAT activity of 47%4% ( of two independentn = 5
experiments) of wild type was observed. This is not sig-
nificantly different from the 50% expected value, which
suggests that formation of the enzymatically active wild-
type MAT dimer was not adversely affected by the pres-
ence of the mutant R264C subunit.
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Figure 3 Pedigree of family B, showing dominant inheritance of
hypermethioninemia. Blackened symbols represent individuals carry-
ing the single-allelic R264H mutation; unblackened symbols represent
normal subjects. Values in parentheses are plasma methionine con-
centrations (in mM [reference range 5–35 mM]). TheMAT1A exon VII
haplotype, described by Chamberlin et al. (1997), is indicated at the
upper right corner of each symbol.
Hypermethioninemic Individuals Carrying an
Autosomal Dominant MAT1A Mutation
Patients 31 and BII-1, as well as patient BI-1, the fa-
ther of BII-1, each carry the single-allelic–dominant
R264H mutation (fig. 2E) (Chamberlin et al. 1997; Na-
gao and Oyanagi 1997). Patient 31, a girl born of un-
related German parents, was identified with plasma
methionine elevated to 231–535 mM. In a crude liver
extract, MAT activity was only questionably diminished
(H. Przyrembel, personal communication; details re-
viewed in a study by Mudd et al. [1998]). Patient BII-
1, a 1.6-year-old boy, with plasma methionine of 233
mM at age 2 mo, was shown to carry the single-allelic
MAT1A R264H mutation with an exon VII haplotype
of 1/4 (fig. 3). Members of his immediate family were
screened for plasma methionine concentrations and for
the presence of the R264H allele. Consistent with the
dominant mode of inheritance, his father, BI-1, in good
health at age 37 years, had moderately elevated plasma
methionine levels (105 mM) and was a heterozygote for
a normal allele and the R264H mutation, with exon VII
haplotype 3/4 (fig. 3). The mother and a sister, with VII
haplotypes 1/1 and 1/3, respectively, have wild-type
MAT1A genes and normal plasma methionine levels (fig.
3).
Discussion
The MAT1A gene is expressed primarily in the liver,
the organ in which synthesis of the predominant portion
of AdoMet occurs (Mudd and Poole 1975; Kotb et al.
1997). AdoMet serves as the methyl donor in the bio-
synthesis of 100 metabolites. Thus, studies of genetic,
metabolic, and clinical aspects of mutations in the
MAT1A gene are of interest. Current evidence estab-
lishes that deleterious MAT1A mutations cause abnor-
mal accumulation of methionine (reviewed in the studies
by Mudd et al. [1995a, 1998]). In the present study, we
report characterization of MAT1A mutations in seven
hypermethioninemic individuals and uncover six novel
mutations: 113GrA/S38N, 255delCA/92X, 791CrT/
R264C, 1006GrA/G336R, 1031ArC/E344A, and
292GfgtrAfgt. To date, a total of 17 MAT1A muta-
tions have been identified among 47 hypermethioni-
nemic individuals (Ubagai et al. 1995; Chamberlin et al.
1996, 1997; Nagao and Oyanagi 1997; Hazelwood et
al. 1998; present study).
The available evidence suggests that the metabolic
and the clinical effects of MAT1A mutations are highly
variable. The majority (32 of 47) of the genotyped indi-
viduals carry a dominant MAT1A mutation, R264H
(Chamberlin et al. 1997; Nagao and Oyanagi 1997;
Mudd et al. 1998). The metabolic result of this single-
allelic mutation is relatively mild elevation of plasma
methionine, which, clinically, appears to be entirely be-
nign, as exemplified by the good health of individual BI-
1 at age 37 years.
The remaining genotypes, all of which behave as au-
tosomal recessive traits, are more heterogeneous with
respect to the severity of the hypermethioninemia and
the clinical states of the individuals carrying the muta-
tions (Ubagai et al. 1995; Chamberlin et al. 1996; pre-
sent study). Nine individuals (G1–G4, 5, 10, 11, 13, and
14) carry only missense mutations in theirMAT1A gene
(table 3). Most such individuals were clinically unaf-
fected at last report, although some were very young at
that time (Gaull et al. 1981; Mudd et al. 1995b, 1998).
Transient expression assays demonstrate that most mu-
tant MATs found in these patients retain significant en-
zymatic activity (Ubagai et al. 1995; Chamberlin et al.
1996). Within this group, patient 5 is perhaps excep-
tional in that, cognitively, she functions less well than
her unaffected siblings. However, she had a normalMRI
of the brain at age 13 years. She carries two mutations,
R264C and G336R. R264C has virtually no enzymatic
activity, whereas G336R retains significantMAT activity
(23% of the level of the wild-type enzyme).Nevertheless,
the persistently extremely high plasma methionine con-
centrations observed in this patient suggest that she may
have less residual MAT I/III activity in vivo than do the
other eight members of this group.
Patients 9 and 1 each carry both missense and inser-
tion or deletion mutations (table 3). The 539insTG mu-
tation in patient 9 yields a severely truncated protein
devoid of MAT activity, whereas his R199C retains 11%
of wild-type activity (Chamberlin et al. 1996). At age 6
years, this patient attained a composite score on the
Stanford-Binet Intelligence Scale that placed him in the
lowest 1% of the population, but, on an MRI of his
brain, white matter was termed unremarkable, and there
was no evidence for gray-matter heterotopia (S. Richter,
personal communication). In patient 1, the 255delCA
mutation also yields a severely truncated proteinwithout
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Table 3
Mutations Identified in the MAT1A Gene that are Transmitted as Autosomal
Recessive Traits
Patient Allele 1 Allele 2 Reference
G1 966TrG/I322M 966TrG/I322M Ubagai et al. (1995)
G2 914TrC/L305P 966TrG/I322M Ubagai et al. (1995)
G3 164CrA/A55D 1070CrT/P357L Ubagai et al. (1995)
G4 1068GrA/R356Q 1132GrA/G378S Chamberlin et al. (1996)
5 791CrT/R264C 1006GrA/G336R Present study
10 595CrT/R199C 595CrT/R199C Chamberlin et al. (1996)
11 595CrT/R199C 595CrT/R199C Chamberlin et al. (1996)
13 595CrT/R199C 595CrT/R199C Chamberlin et al. (1996)
14 966TrG/I322M 1031ArC/E344A Present study
9 539insTG/185X 595CrT/R199C Chamberlin et al. (1996)
1a 113GrA/S38N 255delCA/92X Present study
Ca 827insG/351X 827insG/351X Chamberlin et al. (1996)
Mr C 539insTG/185X 539insTG/185X Hazelwood et al. (1998)
3 539insTG/185X 539insTG/185X Chamberlin et al. (1996)
8a 1043delTG/350X 1043delTG/350X Chamberlin et al. (1996)
7a 292GfgtrAfgt 292GfgtrAfgt Present study
a Manifested neurological problems and/or MRI abnormalities.
MAT activity, but, unlike the situation in patient 9, his
S38N mutation abolishes MAT activity. An MRI study
of the brain of this patient at age 20 years revealed
anomalies of gray matter, the first demonstrated among
patients with isolated hypermethioninemia.
Four patients (C, Mr C, 3, and 8) are homozygous
for deletion/insertion mutations (table 3), yielding trun-
catedMATmutants devoid of enzymatic activity (Cham-
berlin et al. 1996; Hazelwood et al. 1998). Generally,
these patients have the most extreme elevations of
plasma methionine (Gahl et al. 1988; Surtees et al. 1991;
Mudd et al. 1995b). Patient C is homozygous for a
827insG, predicted to encode a truncated protein of 350
amino acids; patient 8 is homozygous for a 1043delTG
mutation, encoding a truncated protein of 349 amino
acids (table 3); and both patients had neurological prob-
lems and demyelination documented by MRI scans at
ages 11 and 9 years, respectively (Surtees et al. 1991;
Mudd et al. 1995b). Patient 3 andMr C are homozygous
for a 539insTG mutation, yielding a truncated polypep-
tide of 184 amino acids (Chamberlin et al. 1996; Ha-
zelwood et al. 1998). However, both are free of neu-
rological problems and neither had suggestions of
demyelination on MRI examinations at ages 43 years
(Hazelwood et al. 1998) and 6.25 years (W. Wilson,
personal communication), respectively. The possibility
has been raised that deleterious interactions may take
place between the abnormal, slightly truncated,MAT1A
a1 subunits synthesized in patients 8 and C and the
normal a2 subunits encoded by MAT2A, whereas sim-
ilar interactions might be less likely with the more-se-
verely truncated a1 subunits produced by patients 3 and
Mr C (Hazelwood et al. 1998).
Patient 7 is the only affected individual demonstrated
to be homozygous for a splicing mutation in theMAT1A
gene. Although the concentration of MAT activity in the
liver of this patient remains unknown, his consistently
high plasma methionine concentrations, comparable to
those found in patients with homozygous null mutations
(Mudd et al. 1995b), suggests that his MAT I/III activity
deficit may be virtually complete. In spite of normal
neurological examinations at ages 4 years and 7 years,
he was found, on MRIs of the brain, to have signs of
demyelination and, at age 7 years, is said, by staff at his
school, to be manifesting poor cognitive skills.
Assays of enzymatic activity of mutantMAT1A cDNA
constructs in transient expression studies provide only
provisional estimates of the contributions of such mu-
tations to MAT I/III activity in vivo. Interactions among
subunits, changes in the state of polymerization, and
other variables may all affect the actual MAT activity
in the liver. Nevertheless, the observations reviewed here
seem to indicate that moderate impairments in MAT I/
III activity are clinically benign. Among patients with
severe impairments in MAT I/III activity, however, there
seems to be a clustering of neurological problems, learn-
ing disabilities, and MRI abnormalities of white matter
and, in one case, gray matter. Nevertheless, clinical prob-
lems are not universal in these individuals. Thus, the
question of a possible causative relationship between
severe deficiency of MAT I/III activity and clinical prob-
lems remains open. Further studies that assess the ge-
netics and the clinical status of individuals with isolated
persistent hypermethioninemia may help to answer this
question.
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